ORGO vs TELA

For growth investors, TELA Bio, Inc.

(TELA) is the stronger pick with 18. 6% revenue growth year-over-year, versus 17. 0% for Organogenesis Holdings Inc. (ORGO). Organogenesis Holdings Inc. (ORGO) offers the better valuation at 16. 7x trailing P/E, making it the more compelling value choice. Analysts rate Organogenesis Holdings Inc. (ORGO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Organogenesis Holdings Inc.

(ORGO) delivered a total return of -88. 1%, compared to -91. 5% for TELA Bio, Inc. (TELA). Over 10 years, the gap is even starker: ORGO returned -74. 2% versus TELA's -91. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TELA Bio, Inc.

(TELA) is the lower-risk stock at 0. 57β versus Organogenesis Holdings Inc. 's 1. 92β — meaning ORGO is approximately 237% more volatile than TELA relative to the S&P 500. On balance sheet safety, Organogenesis Holdings Inc. (ORGO) carries a lower debt/equity ratio of 31% versus 151% for TELA Bio, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TELA Bio, Inc.

(TELA) is pulling ahead at 18. 6% versus 17. 0% for Organogenesis Holdings Inc. (ORGO). On earnings-per-share growth, the picture is similar: Organogenesis Holdings Inc. grew EPS 1600% year-over-year, compared to 34. 8% for TELA Bio, Inc.. Over a 3-year CAGR, TELA leads at 33. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Organogenesis Holdings Inc.

(ORGO) is the more profitable company, earning 6. 6% net margin versus -54. 6% for TELA Bio, Inc. — meaning it keeps 6. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ORGO leads at 10. 0% versus -49. 2% for TELA. At the gross margin level — before operating expenses — ORGO leads at 73. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ORGO (3.

5% yield) pays a dividend. TELA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TELA Bio, Inc.

(TELA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57)). Organogenesis Holdings Inc. (ORGO) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TELA: -91. 8%, ORGO: -74. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

ORGO pays a dividend while TELA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.